Cobo Martín Marta, Fernández Gil Pedro, Crespo Javier
Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
Gastroenterol Hepatol. 2008 Apr;31(4):229-38. doi: 10.1157/13117902.
Nonalcoholic fatty liver disease (NAFLD) is considered to be a hepatic manifestation of metabolic syndrome. The clinicopathologic spectrum ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). Simple steatosis has a relatively benign clinical course, but NASH can progress to cirrhosis and hepatocellular carcinoma. As yet there is no convincingly effective treatment for NAFLD and the best option for these patients might be a multimodal treatment plan targeting obesity, insulin resistance, diabetes mellitus, hyperlipidemia and hypertension.
非酒精性脂肪性肝病(NAFLD)被认为是代谢综合征的肝脏表现。其临床病理谱范围从单纯性脂肪变性到非酒精性脂肪性肝炎(NASH)。单纯性脂肪变性具有相对良性的临床病程,但NASH可进展为肝硬化和肝细胞癌。迄今为止,尚无令人信服的有效治疗方法来治疗NAFLD,对于这些患者而言,最佳选择可能是针对肥胖、胰岛素抵抗、糖尿病、高脂血症和高血压的多模式治疗方案。